ATE413386T1 - Ppar-gamma modulatoren - Google Patents
Ppar-gamma modulatorenInfo
- Publication number
- ATE413386T1 ATE413386T1 AT99901492T AT99901492T ATE413386T1 AT E413386 T1 ATE413386 T1 AT E413386T1 AT 99901492 T AT99901492 T AT 99901492T AT 99901492 T AT99901492 T AT 99901492T AT E413386 T1 ATE413386 T1 AT E413386T1
- Authority
- AT
- Austria
- Prior art keywords
- ppar
- gamma modulators
- modulators
- gamma
- obesity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measurement Of Radiation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7304298P | 1998-01-29 | 1998-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413386T1 true ATE413386T1 (de) | 2008-11-15 |
Family
ID=22111361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99901492T ATE413386T1 (de) | 1998-01-29 | 1999-01-20 | Ppar-gamma modulatoren |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6200995B1 (de) |
| EP (1) | EP1053227B1 (de) |
| JP (1) | JP4253126B2 (de) |
| AT (1) | ATE413386T1 (de) |
| AU (1) | AU759255B2 (de) |
| CA (1) | CA2318731C (de) |
| DE (1) | DE69939864D1 (de) |
| ES (1) | ES2317688T3 (de) |
| WO (1) | WO1999038845A1 (de) |
Families Citing this family (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| JP4253126B2 (ja) * | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ調節剤 |
| MXPA01013199A (es) * | 1999-06-30 | 2003-08-20 | Tularik Inc | Compuestos para la modulacion de la actividad de ppary. |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2001083427A1 (en) * | 2000-04-28 | 2001-11-08 | Sankyo Company, Limited | PPARη MODULATORS |
| AU6118001A (en) * | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) * | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| HK1052351B (en) * | 2000-06-28 | 2006-11-03 | Japan Tobacco Inc. | Benzothiazolyl ppar-gamma modulators |
| US7521463B2 (en) * | 2000-07-31 | 2009-04-21 | University Of Maryland, Baltimore | Immunomodulatory compounds |
| AU2002213467A8 (en) | 2000-10-11 | 2009-07-30 | Chemocentryx Inc | Modulation of ccr4 function |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| EP1911462A3 (de) | 2001-01-26 | 2011-11-30 | Schering Corporation | Zusammensetzungen enthaltend einen Sterolabsorptionshemmer |
| HU230253B1 (hu) | 2001-01-26 | 2015-11-30 | Merck Sharp & Dohme Corp | Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére |
| DK1355644T3 (da) | 2001-01-26 | 2006-10-23 | Schering Corp | Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi |
| AU2002308295B2 (en) | 2001-03-12 | 2007-08-23 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| JP2004529170A (ja) * | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| WO2002089793A1 (en) * | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| AR033879A1 (es) * | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
| EP1406884A1 (de) | 2001-05-11 | 2004-04-14 | Biovitrum Ab | Arylsulfonamid verbindungen zur behandlung von obesitas, typ-ii-diabetes und erkrankungen des zns |
| US7718650B2 (en) | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
| US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| WO2003005025A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| BR0212512A (pt) | 2001-09-14 | 2004-10-26 | Tularik Inc | Composto, composição farmacêutica e métodos para tratar um distúrbio, condição ou doença, elevar os nìveis do colesterol hdl, reduzir os nìveis de triglicerìdeo, tratar diabete, diminuir a resistência à insulina ou diminuir a pressão arterial e modular a ppardelta |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| WO2003035602A1 (en) * | 2001-10-25 | 2003-05-01 | Sankyo Company, Limited | Lipid modulators |
| NZ566263A (en) * | 2002-05-24 | 2009-09-25 | Millennium Pharm Inc | CCR9 inhibitors and methods of use thereof |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| AU2003287965A1 (en) * | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7227035B2 (en) * | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| US20070021466A1 (en) * | 2002-11-18 | 2007-01-25 | Solomon Ungashe | CCR2 inhibitors and methods of use thereof |
| KR100874292B1 (ko) * | 2002-11-18 | 2008-12-18 | 케모센트릭스 | 아릴 술폰아마이드 |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| ES2297382T3 (es) * | 2003-02-14 | 2008-05-01 | Eli Lilly And Company | Derivados de sulfonamida como moduladores de ppar. |
| US20040204472A1 (en) * | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CA2517571C (en) | 2003-03-07 | 2011-07-05 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| EP1646628A1 (de) * | 2003-07-08 | 2006-04-19 | Novartis AG | Benzolsulfonylamino-verbindungen und diese enthaltende pharmazeutische zusammensetzungen |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| GB0327761D0 (en) * | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| KR20070007104A (ko) * | 2004-02-18 | 2007-01-12 | 아스트라제네카 아베 | 화합물 |
| BRPI0507746A (pt) * | 2004-02-18 | 2007-07-10 | Astrazeneca Ab | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto |
| US20050250820A1 (en) * | 2004-03-08 | 2005-11-10 | Amgen Inc. | Therapeutic modulation of PPARgamma activity |
| US7262318B2 (en) | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
| EP1734970B1 (de) | 2004-03-12 | 2014-12-31 | Intercept Pharmaceuticals, Inc. | Behandlung von fibrose mit fxr-liganden |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| US7173031B2 (en) | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| WO2006020830A2 (en) * | 2004-08-12 | 2006-02-23 | Amgen Inc. | Bisaryl-sulfonamides |
| KR20070085371A (ko) | 2004-10-16 | 2007-08-27 | 아스트라제네카 아베 | 페녹시 벤즈아미드 화합물의 제조 방법 |
| GB0423043D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| GB0423044D0 (en) * | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| SE0402635D0 (sv) * | 2004-10-29 | 2004-10-29 | Astrazeneca Ab | Chemical compounds |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| EP1891069A1 (de) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenylsubstituierte imidazol[4,5b]pyridin/pyrazin- und purinderivate als glucokinasemodulatoren |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| JP2009500442A (ja) * | 2005-07-09 | 2009-01-08 | アストラゼネカ アクチボラグ | ２型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての２−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物 |
| KR101346902B1 (ko) * | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| EP2027113A1 (de) * | 2005-07-09 | 2009-02-25 | AstraZeneca AB | Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes |
| US9202182B2 (en) * | 2005-08-11 | 2015-12-01 | International Business Machines Corporation | Method and system for analyzing business architecture |
| CA2624102A1 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| TW200738621A (en) * | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| TW200825060A (en) * | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| TW200829578A (en) | 2006-11-23 | 2008-07-16 | Astrazeneca Ab | Chemical compounds 537 |
| KR20090090390A (ko) * | 2006-12-21 | 2009-08-25 | 아스트라제네카 아베 | Ｇｌｋ 활성제로서 유용한 신규 결정 화합물 |
| JO2754B1 (en) | 2006-12-21 | 2014-03-15 | استرازينكا ايه بي | Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders |
| AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
| UY31832A (es) | 2008-05-20 | 2010-01-05 | Astrazeneca Ab | Derivados de indazol sustituidos con fenilo y benzodioxinilo |
| EA020310B1 (ru) | 2008-07-30 | 2014-10-30 | Интерсепт Фармасьютикалз, Инк. | Модуляторы рецептора tgr5 и их применение |
| EP2324028A2 (de) * | 2008-08-04 | 2011-05-25 | AstraZeneca AB | Therapeutische mittel 414 |
| ES2663948T3 (es) | 2008-11-19 | 2018-04-17 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y método de uso de los mismos |
| MX2011007036A (es) | 2008-12-30 | 2011-07-20 | Pulmagen Therapeutics Inflammation Ltd | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios. |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| WO2010116177A1 (en) | 2009-04-09 | 2010-10-14 | Astrazeneca Ab | A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity |
| AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
| BR112012016111B1 (pt) * | 2010-01-04 | 2017-06-13 | Nippon Soda Co | composto heterocíclico contendo nitrogênio, e, fungicida agrícola |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| CA2811634C (en) | 2010-09-21 | 2019-01-15 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| DK2624695T3 (en) | 2010-10-08 | 2016-01-04 | Nivalis Therapeutics Inc | NOVEL SUBSTITUTED quinoline-RELATIONS AS S-NITROSOGLUTATHIONREDUKTASEINHIBITORER |
| AU2011343518B2 (en) | 2010-12-16 | 2016-11-10 | Nivalis Therapeutics, Inc. | Novel substituted bicyclic aromatic compounds as S-nitrosoglutathione reductase inhibitors |
| WO2012103333A1 (en) * | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
| AR086411A1 (es) | 2011-05-20 | 2013-12-11 | Nippon Soda Co | Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| NZ734451A (en) | 2012-06-19 | 2018-12-21 | Intercept Pharmaceuticals Inc | Preparation, uses and solid forms of obeticholic acid |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| US8993771B2 (en) | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| US9400280B2 (en) | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017044766A1 (en) | 2015-09-10 | 2017-03-16 | Nivalis Therapeutics, Inc. | Solid forms of an s-nitrosoglutathione reductase inhibitor |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
| MX2021008010A (es) | 2018-12-31 | 2021-10-13 | Coherus Biosciences Inc | Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| EP3946336A1 (de) | 2019-04-02 | 2022-02-09 | Coherus Biosciences, Inc. | Zusammensetzungen und verfahren zur behandlung von nichtalkoholischen fettleberkrankheiten (nafld) |
| WO2020205026A1 (en) | 2019-04-04 | 2020-10-08 | Christos Mantzoros | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US20220288054A1 (en) | 2019-04-04 | 2022-09-15 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946334A1 (de) | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Zusammensetzungen und verfahren zur behandlung von nichtalkoholischen fettleberkrankheiten (nafld) |
| US20220288053A1 (en) | 2019-04-04 | 2022-09-15 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| WO2020243058A1 (en) | 2019-05-30 | 2020-12-03 | Coherus Biosciences, Inc. | Compositions and methods to treat cancer |
| WO2021076616A1 (en) | 2019-10-15 | 2021-04-22 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| WO2022051318A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a thyroid receptor beta agonist |
| WO2022051323A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a ppar agonist |
| WO2022051319A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a dpp-4 inhibitor |
| WO2022051316A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a sglt-2 inhibitor |
| WO2022051321A1 (en) | 2020-09-03 | 2022-03-10 | Coherus Biosciences, Inc. | Fixed dose combinations of chs-131 and a fxr agonist |
| CN113912669A (zh) * | 2021-06-28 | 2022-01-11 | 北京大学深圳研究生院 | 基于环构象的抗菌化合物设计、合成及应用 |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2407309A (en) | 1942-02-04 | 1946-09-10 | Squibb & Sons Inc | Chemotherapeutic agents of the sulphonamide type |
| CH362688A (de) | 1957-09-10 | 1962-06-30 | Geigy Ag J R | Verfahren zur Herstellung von neuen Arylsulfonarylamiden |
| US3033870A (en) * | 1958-03-24 | 1962-05-08 | Ciba Pharm Prod Inc | Certain derivatives of 4-(aminophenylmercapto)-pyridine |
| US3700773A (en) | 1969-06-25 | 1972-10-24 | Merck & Co Inc | Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation |
| US3686192A (en) | 1971-01-04 | 1972-08-22 | Minnesota Mining & Mfg | Substituted pyridine derivatives |
| US4061642A (en) | 1972-06-22 | 1977-12-06 | Cassella Farbwerke Mainkur Ag | 2,4,6-Trisubstituted-3-pyridine carboxamides |
| US4003734A (en) | 1974-01-22 | 1977-01-18 | The Dow Chemical Company | Substituted pyridinyloxy(thio)phenyl-acetamides, -ureas and urea derivatives and herbicidal compositions and methods containing said compounds |
| CH592411A5 (en) * | 1974-04-18 | 1977-10-31 | Ciba Geigy Ag | Phenoxymethyl- and phenylthiomethyl-pyridine derivs - with insecticidal, acaricidal and plant-growth regulating activity |
| US4013621A (en) | 1975-04-29 | 1977-03-22 | Ciba-Geigy Corporation | Substituted sulfonamide derivatives of hindered phenols and stabilized compositions |
| GB2009146B (en) | 1977-11-29 | 1982-03-24 | Ishihara Sangyo Kaisha | Sulphonanilide copmouds and herbicidal compositions therof |
| NZ191078A (en) * | 1978-08-08 | 1982-05-31 | Ici Australia Ltd | Bis(pyrimidyloxy) benzenes bis(pyrimidylthio)benzenes and prymidyloxy-pyrimidyl thiobenzens and herbicidal compositions |
| US4289876A (en) | 1978-11-24 | 1981-09-15 | Bristol-Myers Company | Antisecretory agents |
| JPS5579369A (en) | 1978-12-13 | 1980-06-14 | Ishihara Sangyo Kaisha Ltd | Urea compound, its preparation, and insecticide comprising it |
| EP0069585B1 (de) | 1981-07-06 | 1985-07-03 | EASTMAN KODAK COMPANY (a New Jersey corporation) | Farbbildende Sulfonamidodiphenylamine, photographische Elemente die diese enthalten und entsprechende Sulfonimidefarbstoffe |
| US4499304A (en) | 1981-07-06 | 1985-02-12 | Eastman Kodak Company | Color-forming sulfonamidodiphenylamines and corresponding sulfonimide dyes |
| US4577028A (en) | 1981-10-20 | 1986-03-18 | Ciba-Geigy Corporation | 5-Haloalkyl-pyridines |
| US4565568A (en) | 1982-06-18 | 1986-01-21 | The Dow Chemical Company | Pyridyl(oxy/thio)phenoxy compounds, herbicidal compositions and methods |
| US4731090A (en) | 1983-12-23 | 1988-03-15 | Ciba-Geigy Corporation | Process for protecting keratinous material from attack by insects feed on keratin with pyridyloxytrifluoromethanesulfonanilides |
| US4549901A (en) | 1984-02-16 | 1985-10-29 | Stauffer Chemical Company | 2-[4-(Substituted aryl)phenoxy]-N-substituted-phenylsulfonyl propionamides having herbicidal properties |
| FI864138A7 (fi) | 1985-10-16 | 1987-04-17 | Fisons Plc | Heterocykliska blandningar. |
| US4651419A (en) * | 1985-11-08 | 1987-03-24 | Reed Jr August D | Double ended single blade knife |
| DE3545570A1 (de) | 1985-12-21 | 1987-06-25 | Hoechst Ag | Neue pyridin-derivate und deren n-oxide, verfahren zu ihrer herstellung und ihre verwendung als zwischenprodukte |
| US4866079A (en) | 1986-03-19 | 1989-09-12 | Ciba-Geigy Corporation | N-pyridyloxyphenylisothioureas and the use thereof in pest control |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| US5202336A (en) | 1986-09-24 | 1993-04-13 | Bayer Aktiengesellschaft | Antiflammatory quinolin methoxy phenylsulphonamides |
| AU604771B2 (en) | 1986-09-27 | 1991-01-03 | Fisons Plc | Pyridinylphenylthio and pyridinylphenylsulphinyl benzimidazone derivatives |
| JPS646245A (en) | 1987-02-20 | 1989-01-10 | Sumitomo Chemical Co | Benzylamine derivative, production thereof and germicide containing said derivative as active ingredient |
| US4670045A (en) | 1987-04-07 | 1987-06-02 | The Dow Chemical Company | Fungicidal control employing ester derivatives of 4,6-disubstituted 2-pyridinols |
| GB8724252D0 (en) | 1987-10-15 | 1987-11-18 | Ici Plc | Fungicides |
| JPS646245U (de) | 1987-06-30 | 1989-01-13 | ||
| JPH01156953A (ja) * | 1987-09-01 | 1989-06-20 | Hokko Chem Ind Co Ltd | ベンゼンスルホンアニリド誘導体および農園芸用殺菌剤 |
| DE3852621D1 (de) | 1987-12-07 | 1995-02-09 | Ciba Geigy Ag | 3-Aminobenzoylphenylharnstoffe. |
| DE3823318A1 (de) | 1988-07-09 | 1990-02-22 | Bayer Ag | (hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten |
| GB8820115D0 (en) | 1988-08-24 | 1988-09-28 | Ici Plc | Insecticidal compounds |
| DE3905075A1 (de) | 1989-02-18 | 1990-08-30 | Hoechst Ag | Benzolsulfonamide und verfahren zu ihrer herstellung |
| ZA913760B (en) | 1990-05-24 | 1992-02-26 | Sumitomo Chemical Co | Pyridine derivatives,their production processes and their compounds for control of insect pests |
| GB9015658D0 (en) | 1990-07-17 | 1990-09-05 | Shell Int Research | Herbicidal compounds |
| DE69129611T2 (de) | 1990-08-20 | 1998-12-17 | Eisai Co., Ltd., Tokio/Tokyo | Sulfonamid-Derivate |
| NZ239846A (en) | 1990-09-27 | 1994-11-25 | Merck & Co Inc | Sulphonamide derivatives and pharmaceutical compositions thereof |
| JP3188286B2 (ja) | 1991-08-20 | 2001-07-16 | 塩野義製薬株式会社 | フェニルメトキシイミノ化合物およびそれを用いる農業用殺菌剤 |
| US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| US5578611A (en) * | 1992-11-13 | 1996-11-26 | Synaptic Pharmaceutical Corporation | Use of α-1C specific compounds to treat benign prostatic hyperplasia |
| JPH06199047A (ja) | 1993-01-08 | 1994-07-19 | New Oji Paper Co Ltd | 感熱記録体 |
| US5643914A (en) | 1993-03-02 | 1997-07-01 | Smithkline Beecham Corporation | Pharmaceutical pyridine compounds |
| JP3894949B2 (ja) | 1993-06-30 | 2007-03-22 | ザ、ウェルカム、ファンデーション、リミテッド | 抗アテローム性動脈硬化症ジアリール化合物 |
| US5716993A (en) | 1993-12-27 | 1998-02-10 | Eisai Co., Ltd. | Anthranilic acid derivatives |
| WO1995033462A1 (en) * | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
| US5545669A (en) | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
| US5684195A (en) | 1994-07-14 | 1997-11-04 | G. D. Searle & Co. | Method of preparing sulfmonamides from sulfones |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (de) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
| US5814646A (en) | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
| US6022897A (en) | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| US5939442A (en) | 1995-06-07 | 1999-08-17 | The Salk Institute For Biological Studies | Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof |
| TWI238064B (en) | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| WO1997000857A1 (fr) * | 1995-06-21 | 1997-01-09 | Otsuka Kagaku Kabushiki Kaisha | Derives de sulfonamides et insecticide, miticide et nematicide les contenant |
| CA2204616C (en) | 1995-09-18 | 2002-12-17 | Ranjan Mukherjee | Ppar gamma antagonists for treating obesity |
| PT896533E (pt) * | 1996-02-22 | 2004-02-27 | Tularik Inc | Pentafluorobenzenosulfonamidas e analogos |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| JPH09255656A (ja) | 1996-03-28 | 1997-09-30 | Hiroyoshi Hidaka | スルフォンアミド誘導体及びこれを含有する医薬 |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US6294559B1 (en) | 1996-05-02 | 2001-09-25 | Merck & Co., Inc. | Antiproliferative agents associated with peroxisome proliferator activated receptors gamma1 and gamma2 |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| JP3243733B2 (ja) | 1996-08-07 | 2002-01-07 | 雪印乳業株式会社 | 新規イソキノリン誘導体 |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| AU735137B2 (en) | 1997-02-21 | 2001-07-05 | Bayer Intellectual Property Gmbh | Arylsulphonamides and analogues and their use for the treatment and neurovegetative disorders |
| DE69809827D1 (de) * | 1997-03-31 | 2003-01-16 | Korea Res Inst Chem Tech | Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung |
| PH11998001072B1 (en) | 1997-05-07 | 2006-11-21 | Univ Pittsburgh | Inhibitors of protein isoprenyl transferases |
| AU745081B2 (en) | 1997-06-27 | 2002-03-14 | Fujisawa Pharmaceutical Co., Ltd. | Sulfonamide compounds and medicinal use thereof |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| JP4253126B2 (ja) | 1998-01-29 | 2009-04-08 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ調節剤 |
| JP4327915B2 (ja) | 1998-03-30 | 2009-09-09 | 株式会社デ・ウエスタン・セラピテクス研究所 | スルフォンアミド誘導体 |
| WO1999055663A1 (en) | 1998-04-29 | 1999-11-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| HN1998000027A (es) | 1998-08-19 | 1999-06-02 | Bayer Ip Gmbh | Arilsulfonamidas y analagos |
| DE19837627A1 (de) | 1998-08-19 | 2000-02-24 | Bayer Ag | Neue Aminosäureester von Arylsulfonamiden und Analoga |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| GB9818914D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| ES2253930T3 (es) | 1998-09-18 | 2006-06-01 | ABBOTT GMBH & CO. KG | 4-aminopirrolopirimidinas como inhibidores de quinasa. |
| US6586475B1 (en) | 1998-11-20 | 2003-07-01 | Takeda Chemical Industries, Ltd. | β-amyloid protein production/secretion inhibitors |
| US6204288B1 (en) | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| US6202336B1 (en) * | 1999-05-24 | 2001-03-20 | Allan E. Audino | Safety device for firearms |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| AU1215701A (en) | 1999-10-22 | 2001-05-08 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
| CA2325358C (en) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
| AU6118001A (en) | 2000-05-03 | 2001-11-12 | Tularik Inc | Combination therapeutic compositions and methods of use |
| US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
-
1999
- 1999-01-20 JP JP2000530082A patent/JP4253126B2/ja not_active Expired - Fee Related
- 1999-01-20 AT AT99901492T patent/ATE413386T1/de not_active IP Right Cessation
- 1999-01-20 WO PCT/US1999/001147 patent/WO1999038845A1/en not_active Ceased
- 1999-01-20 EP EP99901492A patent/EP1053227B1/de not_active Expired - Lifetime
- 1999-01-20 AU AU21176/99A patent/AU759255B2/en not_active Ceased
- 1999-01-20 ES ES99901492T patent/ES2317688T3/es not_active Expired - Lifetime
- 1999-01-20 DE DE69939864T patent/DE69939864D1/de not_active Expired - Lifetime
- 1999-01-20 CA CA2318731A patent/CA2318731C/en not_active Expired - Fee Related
- 1999-01-20 US US09/234,327 patent/US6200995B1/en not_active Expired - Lifetime
-
2000
- 2000-12-19 US US09/741,415 patent/US6620827B2/en not_active Expired - Fee Related
-
2002
- 2002-04-15 US US10/123,298 patent/US7439242B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2117699A (en) | 1999-08-16 |
| JP2002501945A (ja) | 2002-01-22 |
| AU759255B2 (en) | 2003-04-10 |
| US6200995B1 (en) | 2001-03-13 |
| EP1053227A1 (de) | 2000-11-22 |
| US7439242B2 (en) | 2008-10-21 |
| US6620827B2 (en) | 2003-09-16 |
| WO1999038845A1 (en) | 1999-08-05 |
| US20010027200A1 (en) | 2001-10-04 |
| CA2318731A1 (en) | 1999-08-05 |
| CA2318731C (en) | 2012-05-29 |
| DE69939864D1 (de) | 2008-12-18 |
| ES2317688T3 (es) | 2009-04-16 |
| EP1053227B1 (de) | 2008-11-05 |
| US20030088103A1 (en) | 2003-05-08 |
| JP4253126B2 (ja) | 2009-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69939864D1 (de) | Ppar-gamma modulatoren | |
| NZ516455A (en) | Compounds for the modulation of PPARgamma activity | |
| DE69929996D1 (de) | Pharmazeutisches mittel zur behandlung von diabetes | |
| NO20063000L (no) | Kombinasjon og farmasøytisk blanding for behandling av diabetes samt anvendelse derav. | |
| NO20061736L (no) | Krystallform av epotilon B | |
| IL151313A0 (en) | Lipase containing pharmaceutical compositions | |
| DE122009000012I1 (de) | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen. | |
| DK0760848T3 (da) | Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf | |
| MY180762A (en) | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators. | |
| DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
| DE69934877D1 (de) | Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen | |
| DE69905170T2 (de) | Thiazolopyrimidinderivate | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
| ATE255632T1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
| IL143516A0 (en) | COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
| DK0977871T3 (da) | Neurotrypsin | |
| DE69834937D1 (de) | Antibiotika zur behandlung von magengeschwuren | |
| PT1092040E (pt) | Metodos de inibicao helicobacter pylori | |
| ATE165594T1 (de) | Triarylethylenderivate zur therapeutischen verwendung | |
| MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. | |
| BR0108187A (pt) | Moléculas trade e usos relacionados com as mesmas | |
| IT1290910B1 (it) | 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |